Piper Sandler initiated coverage on Revolution Medicines with a new price target
$RVMD
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Piper Sandler initiated coverage of Revolution Medicines with a rating of Overweight and set a new price target of $43.00